This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wandt, H. Articles by Gallmeier, W. M. Search for Related Content PubMed PubMed Citation Articles by Wandt, H. Articles by Gallmeier, W. M.

New Strategies for Prophylactic Platelet Transfusion in Patients with Hematologic Diseases

^a 5th Medical Department and Institute of Medical Oncology and Hamatology, Nüremberg, Germany; ^b Medical Clinic I, Technical University, Dresden, Germany

Correspondence: Hannes Wandt, M.D., 5th Medical Department and Institute of Medical Oncology and Hamatology, Prof.-Ernst-Nathan-Str. 1, D-90340 Nürnberg, Germany. Telephone: 49-911-3-98-36-50; Fax: 49-911-3-98-36-57; e-mail: wandt{at}klinikum-nuernberg.de

There is an increasing demand for platelet transfusions due to intensive chemotherapy and blood stem cell or bone marrow transplantation for the treatment of hematologic and oncologic diseases. There has been a long-lasting debate over whether the traditional threshold for prophylactic platelet transfusion of 20,000/µl is really necessary to prevent hemorrhagic complications. During the last 10 years several studies with more than 1,000 patients together have proven the safety of a platelet transfusion trigger of 10,000/µl or even lower when patients are clinically stable without active bleeding. This experience has been mostly gathered in patients with acute leukemia. But this stringent platelet transfusion policy can be used also after blood stem cell and bone marrow transplantation. In stable patients with aplastic anemia and myelodysplasia, prophylactic transfusions should be replaced in most patients by a therapeutic transfusion strategy. Such restrictive platelet transfusion strategies decrease the risk of infectious disease transmission, immunization, and febrile transfusion reactions. Besides reduced hospital visits and a shorter hospital stay for the patients, the costs for platelet transfusions are lowered by 20%-30% compared with traditional transfusion strategies. The decision to administer platelet transfusions should incorporate individual clinical characteristics of the patients and not simply be a reflexive reaction to the platelet count. Further clinical studies are needed to answer the still open question of whether patients with acute leukemia should also be transfused therapeutically rather than prophylactically when they are in stable condition without signs of active bleeding.

Key Words. Platelet transfusion trigger • Prophylactic transfusion • Thrombocytopenia and transfusion • Hematologic diseases and transfusion